Latest Treatment of ulcerative colitis Stories

2008-10-06 09:00:09

PHILADELPHIA, Oct. 6 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, announced the results from a multidisciplinary analysis of in vitro and in vivo data of LIALDA(R) (mesalamine) versus Asacol(R) (mesalamine) that investigated factors including transit and disintegration of tablets along with tablet coating thickness that may affect a consistent release of 5-aminosalicylate acid (5-ASA) in both therapies. This analysis will be presented at The American...

2008-08-13 09:01:16

WALTHAM, Mass., Aug. 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that robust annual five percent growth through 2017 in the ulcerative colitis drug market will be driven by strong uptake of Abbott/Eisai's Humira, Centocor/Schering-Plough/Mitsubishi Tanabe Pharma/Janssen's golimumab and Bristol-Myers Squibb's Orencia, following the expected approvals and launches of these three biologic agents...

2008-06-24 09:02:18

By PETER GOTT Dear Dr. Gott: Can you give me some advice about ulcerative colitis? I have had this condition for 25 years. I have seen several doctors and taken lots of medication over the years and had to quit my job because of it. My doctor insists it is caused by bacteria, but I was wondering if it could be caused by allergies. Dear Reader: Ulcerative colitis is a disease of the colon and rectum. It causes ulcers in the intestinal lining and inflammation. The ulcers form where the...

2007-03-19 12:00:19

BASINGSTOKE, England and PHILADELPHIA, March 19 /PRNewswire-FirstCall/ -- Shire plc today announced the availability of LIALDA(TM) (mesalamine) with MMX(TM) Technology, indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC), a type of inflammatory bowel disease. LIALDA is the first and only FDA-approved once daily oral formulation of mesalamine. The U.S. Food and Drug Administration (FDA) approved LIALDA on January 16, 2007. LIALDA is...

2006-06-15 22:56:41

By Anthony J. Brown, MD NEW YORK (Reuters Health) - A common operation for ulcerative colitis renders nearly 50 percent of female patients infertile, according to a new report. By contrast, when the disease is managed with medications alone, the infertility rate is 15 percent, similar to the rate seen in healthy women. Ulcerative colitis is a serious disease in which the body's immune cells attack the inner lining of the large intestine or colon resulting in severe bouts of bloody...

2006-02-15 12:15:00

By Karla Gale NEW YORK -- In a study of patients with dormant ulcerative colitis, a 14-day course of the selective COX-2 inhibitor, Celebrex (celecoxib), did not cause disease exacerbation. However, another study showed that use of older, nonselective anti-inflammatory agents can quickly induce relapse in patients with Crohn's disease and ulcerative colitis. However, this study also found that short-term treatment with a Celebrex-like drug or with low-dose aspirin is well tolerated. The...

Word of the Day
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'